XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Note 4 - Balance Sheet Components
9 Months Ended
Sep. 30, 2022
Notes to Financial Statements  
Supplemental Balance Sheet Disclosures [Text Block]

NOTE 4.  Balance Sheet Components

 

 

(a)

Cash, Cash Equivalents and Investments

 

Cash, cash equivalents and investments consisted of the following (in thousands):

 

  

Amortized

  

Gross Unrealized

  

Estimated

  

Cash and Cash

  

Short-Term

  

Long-Term

 
  

Cost

  

Gains

  

Losses

  

Fair Value

  

Equivalents

  

Investments

  

Investments

 

September 30, 2022

                            

Cash at banks

 $19,895  $  $  $19,895  $19,895  $  $ 

Money market funds

  30,873         30,873   30,873       

U.S. Treasury securities

  49,841      (452)  49,389      49,389    

Commercial paper

  8,959         8,959      8,959    

Corporate debt securities

  5,716      (65)  5,651      5,651    

Total

 $115,284  $  $(517) $114,767  $50,768  $63,999  $ 

 

 

  

Amortized

  

Gross Unrealized

  

Estimated

  

Cash and Cash

  

Short-Term

  

Long-Term

 
  

Cost

  

Gains

  

Losses

  

Fair Value

  

Equivalents

  

Investments

  

Investments

 

December 31, 2021

                            

Cash at banks

 $72,767  $  $  $72,767  $72,767  $  $ 

Money market funds

  70,978         70,978   70,978       

U.S. Treasury securities

  25,055      (58)  24,997      12,022   12,975 

Commercial paper

  7,491         7,491      7,491    

Corporate debt securities

  6,480      (16)  6,464      3,229   3,235 

Total

 $182,771  $  $(74) $182,697  $143,745  $22,742  $16,210 

 

 

(b)

Accounts Receivable 

 

Accounts receivable comprises royalties receivable of nil and $71,000 as of September 30, 2022 and December 31, 2021, respectively. The Company has provided no allowance for uncollectible accounts as of  September 30, 2022 and December 31, 2021.

 

 

(c)

Property and Equipment, Net

 

Property and equipment, net consists of the following (in thousands):

 

  

September 30, 2022

  

December 31, 2021

 
    

Laboratory equipment

 $7,465  $5,057 

Office and computer equipment

  767   481 

Leasehold improvements

  1,063   1,063 

Construction in progress

  5,596   1,305 

Total property and equipment

  14,891   7,906 

Less: accumulated depreciation

  (2,611)  (1,305)

Property and equipment, net

 $12,280  $6,601 

 

Depreciation expense was $489,000 and $211,000 for the three months ended September 30, 2022 and 2021, respectively, and $1.3 million and $406,000 for the nine months ended September 30, 2022 and 2021, respectively. There were no impairments of the Company’s property and equipment recorded in the nine months ended September 30, 2022 or 2021.

 

 

(d)

Right-of-Use Assets, Net

 

Right-of-use assets, net comprises facilities of $26.6 million and $13.2 million as of September 30, 2022 and December 31, 2021, respectively.

 

 

 

 

(e)

Intangible Assets, Net

 

Intangible assets comprise developed technology and intellectual property. Intangible assets are carried at cost less accumulated amortization. Amortization is computed using the straight-line method over useful lives ranging from 1.3 to 11.75 years for developed technology and 20 years for intellectual property. As of September 30, 2022, developed technology and intellectual property had remaining lives of 7.1 and 5.25 years, respectively. Intangible assets consist of the following (in thousands):

 

  

September 30, 2022

  

December 31, 2021

 
    

Developed technology

 $10,600  $10,600 

Intellectual property

  80   80 

Total cost

  10,680   10,680 

Less: accumulated amortization

  (1,069)  (56)

Intangible assets, net

 $9,611  $10,624 

 

Total amortization expense for the three months ended September 30, 2022 and 2021, was $338,000 and $433,000, respectively, and $1.0 million and $1.3 million for the nine months ended September 30, 2022 and 2021, respectively. As of September 30, 2022, the estimated future amortization expense by year is as follows (in thousands):

 

Year Ending December 31,

 

Amount

 

2022 (three months remaining)

 $338 

2023

  1,350 

2024

  1,350 

2025

  1,350 

2026

  1,350 

Thereafter

  3,873 

Total

 $9,611 

 

 

(f)

Goodwill

 

Goodwill, which represents the excess of the purchase price over the fair value of assets acquired, comprises $4.5 million as of September 30, 2022 and December 31, 2021. As of September 30, 2022, there have been no indicators of impairment.

 

 

(g)

Other Accrued Liabilities

 

Other accrued liabilities consist of the following (in thousands):

 

  

September 30, 2022

  

December 31, 2021

 
         

Accrued compensation

 $3,809  $2,786 

Accrued clinical and manufacturing expenses

  1,203   986 

Accrued professional and consulting services

  715   556 

Accrued litigation settlement

  2,000    

Other liabilities, current portion

  2,617   736 

Total

 $10,344  $5,064